KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer

The KRAS gene frequently mutates in colorectal cancer (CRC). Here we investigated the prognostic and predictive role of KRAS mutation in patients with stage II or III CRC.

Source: Molecular Oncology - March 26, 2015 Category: Cancer & Oncology Authors: Yanhong Deng, Li Wang, Shuyun Tan, George P. Kim, Ruoxu Dou, Dianke Chen, Yue Cai, Xinhui Fu, Lei Wang, Jun Zhu, Jianping Wang Source Type: research